scholarly journals Implication of Human Bacterial Gut Microbiota on Immune-Mediated and Autoimmune Dermatological Diseases and Their Comorbidities: A Narrative Review

2021 ◽  
Author(s):  
Roberta Colucci ◽  
Silvia Moretti
Keyword(s):  
Gut Microbiota ◽  
Narrative Review ◽  
Dermatological Diseases ◽  
Immune Mediated

scholarly journals Modulation of Gut Microbiota for the Prevention and Treatment of COVID-19

2021 ◽  
Vol 10 (13) ◽  
pp. 2903
Author(s):  
Jiezhong Chen ◽  
Luis Vitetta
Keyword(s):  
Clinical Trials ◽  
Trace Elements ◽  
Gut Microbiota ◽  
Human Health ◽  
Intestinal Microbiota ◽  
Narrative Review ◽  
Bacterial Metabolites ◽  
Gut Dysbiosis ◽  
Prevention And Treatment

The gut microbiota is well known to exert multiple benefits on human health including protection from disease causing pathobiont microbes. It has been recognized that healthy intestinal microbiota is of great importance in the pathogenesis of COVID-19. Gut dysbiosis caused by various reasons is associated with severe COVID-19. Therefore, the modulation of gut microbiota and supplementation of commensal bacterial metabolites could reduce the severity of COVID-19. Many approaches have been studied to improve gut microbiota in COVID-19 including probiotics, bacterial metabolites, and prebiotics, as well as nutraceuticals and trace elements. So far, 19 clinical trials for testing the efficacy of probiotics and synbiotics in COVID-19 prevention and treatment are ongoing. In this narrative review, we summarize the effects of various approaches on the prevention and treatment of COVID-19 and discuss associated mechanisms.

scholarly journals Strongyloides stercoralis Infestation in a Child: How a Nematode Can Affect Gut Microbiota

2021 ◽  
Vol 22 (4) ◽  
pp. 2131
Author(s):  
Stefania Pane ◽  
Anna Sacco ◽  
Andrea Iorio ◽  
Lorenza Romani ◽  
Lorenza Putignani
Keyword(s):  
Gut Microbiota ◽  
Bacterial Species ◽  
Alpha Diversity ◽  
Strongyloides Stercoralis ◽  
Pulmonary Involvement ◽  
Diversity Indices ◽  
Parasite Infection ◽  
Intestinal Nematode ◽  
Immune Mediated ◽  
Stool Samples

Background: Strongyloidiasis is a neglected tropical disease caused by the intestinal nematode Strongyloides stercoralis and characterized by gastrointestinal and pulmonary involvement. We report a pediatric case of strongyloidiasis to underline the response of the host microbiota to the perturbation induced by the nematode. Methods: We performed a 16S rRNA-metagenomic analysis of the gut microbiota of a 7-year-old female during and after S. stercolaris infection, investigating three time-point of stool samples’ ecology: T0- during parasite infection, T1- a month after parasite infection, and T2- two months after parasite infection. Targeted-metagenomics were used to investigate ecology and to predict the functional pathways of the gut microbiota. Results: an increase in the alpha-diversity indices in T0-T1 samples was observed compared to T2 and healthy controls (CTRLs). Beta-diversity analysis showed a shift in the relative abundance of specific gut bacterial species from T0 to T2 samples. Moreover, the functional prediction of the targeted-metagenomics profiles suggested an enrichment of microbial glycan and carbohydrate metabolisms in the T0 sample compared with CTRLs. Conclusions: The herein report reinforces the literature suggestion of a putative direct or immune-mediated ability of S. stercolaris to promote the increase in bacterial diversity.

Gut microbiota and non-alcoholic fatty liver disease: a narrative review

2021 ◽  
Author(s):  
Ludovico Abenavoli ◽  
Anna C. Procopio ◽  
Emidio Scarpellini ◽  
Natale Polimeni ◽  
Isabella Aquila ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Narrative Review ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21024-e21024
Author(s):  
Justin Chau ◽  
Meeta Yadav ◽  
Ben Liu ◽  
Muhammad Furqan ◽  
Qun Dai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Gut Microbiota ◽  
Treatment Response ◽  
Gut Microbiome ◽  
Operational Taxonomic Unit ◽  
Geographic Region ◽  
Organ Function ◽  
Immune Mediated ◽  
Α Diversity ◽  
Clinical Trial Information

e21024 Background: Though the gut microbiome has been associated with immunotherapy (ICI) efficacy in certain cancers, similar correlations between microbiomes at other body sites with treatment response and immune related adverse events (irAEs) in lung cancer (LC) patients receiving ICIs have not been made. We designed a prospective cohort study conducted from 2018-2020 at a single-center academic institution to assess for correlations between the microbiome in various body sites with treatment response and development of irAEs in LC patients treated with ICIs. Methods: Patients with histopathologically confirmed, unresectable/advanced/metastatic LC planned to undergo ICI-based therapy were enrolled between September 2018 and June 2019. Patients must have had measurable disease, ECOG 0-2, and good organ function to be included. Data was collected for analysis from January 2019 to October 2020. Nasal, buccal and gut microbiome samples were obtained prior to ICI initiation, at development of irAEs, improvement of irAEs to grade 1 or less, and at disease progression. 16S rRNA sequenced data was mapped to the SILVA 13.2 database; operational taxonomic unit clusters were analyzed using MicrobiomeAnalyst and METAGENassist. Results: 37 patients were enrolled, and 34 patients were evaluable for this report. 32 healthy controls (HC) from the same geographic region were included to compare baseline gut microbiota. Compared to HC, LC gut microbiota exhibited significantly lower α-diversity. The gut microbiome of patients who did not suffer irAEs were found to have relative enrichment of Bifidobacterium ( p = 0.001) and Desulfovibrio ( p = 0.0002). Responders to combined chemoimmunotherapy exhibited increased Clostridiales ( p = 0.018) but reduced Rikenellaceae ( p = 0.016). In responders to chemoimmunotherapy we also observed enrichment of Finegoldia in nasal microbiome, and increased Megasphaera but reduced Actinobacillus in buccal samples. Longitudinal samples exhibited a trend of α-diversity and certain microbial changes during the development and resolution of irAEs. Conclusions: This pilot study identified significant differences in the gut microbiome between HC and LC patients, and correlates specific bacterial genera to ICI response and irAEs in LC. In addition, it suggests potential predictive utility in nasal and buccal microbiomes, warranting further validation with a larger cohort and mechanistic dissection using preclinical models. Clinical trial information: NCT03688347.

scholarly journals Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A

2020 ◽  
Vol 4 (12) ◽  
pp. 2644-2655
Author(s):  
Julie Tarrant ◽  
Matthew Cormier ◽  
Kate Nesbitt ◽  
Courtney Dwyer ◽  
Christine Hough ◽  
...  
Keyword(s):  
Immune Response ◽  
Gut Microbiota ◽  
Hemophilia A ◽  
Immune Cell ◽  
Short Chain Fatty Acids ◽  
Microbial Metabolites ◽  
Oral Supplementation ◽  
Immune Mediated ◽  
Related Risk ◽  
Cell Transcriptome

Abstract The development of neutralizing FVIII antibodies is the most serious complication of hemophilia A treatment. The currently known patient- and treatment-related risk factors for inhibitor development do not accurately predict this adverse event in all patients. The composition of the gut microbiota has been shown to influence immune-mediated diseases at distant anatomical sites (eg, lungs, brain, and joints). We demonstrate that a disrupted gut microbiota can be created in a mouse model of hemophilia A using a broad-spectrum antibiotic. Under controlled conditions, this sustained dysbiosis was associated with an increase in splenic B cells and the development of higher titer, FVIII-specific immunoglobulin G antibodies after FVIII challenge. Splenic and mesenteric lymph node cytokines, T cells, and dendritic cells were unaffected before administration of FVIII. However, the immune transcriptome of both aforementioned secondary lymphoid organs was significantly modified. Short-chain fatty acids (SCFAs), which are immunomodulatory microbial metabolites, were depleted in cecal contents of the dysbiotic mice. Furthermore, supplementation of the drinking water with butyrate, the most immunologically active SCFA, successfully achieved attenuation of the FVIII immune response. Collectively, data from this exploratory study suggest that the composition of the gut microbiota alters the FVIII immune response via the action of specific microbial metabolites on the immune cell transcriptome and that oral supplementation with butyrate effectively reduces the FVIII immune response.

scholarly journals Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota

2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Jianing Chen ◽  
Yingfeng Wei ◽  
Jianqin He ◽  
Guangying Cui ◽  
Yunan Zhu ◽  
...  
Keyword(s):  
T Cells ◽  
Liver Injury ◽  
Gut Microbiota ◽  
Natural Killer ◽  
Natural Killer T Cells ◽  
Immune Mediated ◽  
Killer T Cells ◽  
Natural Killer T

scholarly journals Extrapulmonary Manifestations of Coronavirus Disease 2019: A Narrative Review

2020 ◽  
Vol 23 (5) ◽  
pp. 604-613
Author(s):  
Ameneh Omidi ◽  
Keyword(s):  
Ethical Issues ◽  
Gastrointestinal Symptoms ◽  
Large Family ◽  
Narrative Review ◽  
Cellular Damage ◽  
Respiratory Dysfunction ◽  
Scientific Databases ◽  
Immune Mediated ◽  
Severity Of The Disease ◽  
Tract Infections

Background and Aim: Coronaviruses are a large family of viruses that are known to cause respiratory tract infections in humans. SARS-CoV-2 is a new type of this family initiated in late 2019 and its related disease is known as Coronavirus Disease 2019 (COVID-19). Common symptoms of COVID-19 include fever, dry cough, fatigue, myalgia, arthralgia and shortness of breath. Methods & Materials: In This narrative review a literature search was conducted in scientific databases including Google Scholar and PubMed to find studies published from December 2019 to May 10 2020 on the role the extrapulmonary manifestations of COVID-19. Ethical Considerations: Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or submission, redundancy) have been completely observed by the authors. Results: In addition to respiratory symptoms, involvement of various organs such as gastrointestinal tract, nervous system, skin, olfactory system, cardiovascular system, liver, kidney, and eyes was also reported. Extrapulmonary manifestations of COVID-19 included anosmia, ageusia, skin rash, chickenpox-like blisters, acute cardiac failure with increased troponin levels, kidney inflammation and edema, common gastrointestinal symptoms (e.g. diarrhea, nausea and vomiting), elevated liver enzyme levels, neurological disorders (e.g. stroke), nonspecific symptoms (e.g. headache and dizziness), and decreased consciousness level. Conclusion: The hypothetical mechanisms of various organ involvements during COVID-19 include immune-mediated inflammation such as cytokine storm, respiratory dysfunction, hypoxemia, cellular damage, or combination of these mechanisms. Further studies should be conducted on the causes of various COVID-19-induced damages to determine the exact relationship between the pathogenesis, prognosis and severity of the disease.

Sign in / Sign up

Export Citation Format

Share Document